Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light–positive lesions diagnosed as atypical
Human Pathology Jun 12, 2019
Pederzoli F, et al. - Considering the possibility that blue light cystoscopy (BLC) using photosensitizing agents improves detection rates of carcinoma in situ (CIS), transurethral biopsies of bladder tumors evaluated with both white light cystoscopy and BLC were retrospectively reviewed (n = 135 samples from 79 patients). Based on the presence/absence of fluorescence under BLC and the final pathological report (CIS/benign/atypical), researchers classified the biopsies. Findings revealed very high sensitivity (92.7%) and negative predictive value (93.5%) of BLC. BLC led to the removal of a number of BLC(+)/atypical lesions (false positive). They identified good interobserver agreement reviewing BLC(+)/atypical lesions. In the diagnosis of CIS, findings still support morphology as the standard criterion in BCL(+) lesions.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries